Proactiveinvestors United Kingdom - Pharmaceuticals RSS feed Proactiveinvestors United Kingdom - Pharmaceuticals feed en Sat, 20 Jan 2018 11:31:41 +0000 Genera CMS Midatech gets US green light to begin trials on a drug that may offer hope to suffers of fatal childhood cancer Tue, 16 Jan 2018 07:30:00 +0000 Amryt Pharma expands route to market for key product Wed, 10 Jan 2018 07:26:00 +0000 Midatech Pharma receives regulatory green light for EU study; cancer product could be launched as early as 2020 Tue, 09 Jan 2018 07:58:00 +0000 Amryt Pharma signs exclusive distributor agreement in Switzerland Mon, 08 Jan 2018 07:28:00 +0000 Shares in Midatech Pharma up 50% after drug developer ties up non-dilutive funding deal Wed, 03 Jan 2018 14:27:00 +0000 Midatech Pharma secures US$15mln debt facility Tue, 02 Jan 2018 14:56:00 +0000 Midatech starts Phase IV trial to test Gelclair oral mucositis gel in stem cell transplant patients Wed, 20 Dec 2017 08:17:00 +0000 Amryt Pharma makes senior hire Wed, 20 Dec 2017 08:08:00 +0000 Midatech heads higher as it receives manufacturing licence extension for its Spanish facility Wed, 22 Nov 2017 08:42:00 +0000 Amryt Pharma inks exclusive Saudi Arabian distribution agreement for its Lojuxta and AP101 drugs Mon, 13 Nov 2017 07:35:00 +0000 Midatech Pharma to raise up to £8mln to accelerate progress of three main drug candidates Thu, 28 Sep 2017 15:10:00 +0100 Amryt Pharma raising €15mln to fund development of breakthrough skin treatment Thu, 21 Sep 2017 15:40:00 +0100 Hedge fund founder Dalio becomes latest to call out bitcoin Tue, 19 Sep 2017 17:26:00 +0100 Amryt Pharma drug exceeds expectations; potential market bigger than anticipated Mon, 04 Sep 2017 10:59:00 +0100 Midatech Pharma submits application for first human clinical trial study of rare cancers treatment Mon, 04 Sep 2017 07:50:00 +0100 Amryt Pharma appoints industry veteran as Vice President of Strategic Alliances and Licensing Wed, 30 Aug 2017 08:00:00 +0100 Quantum Pharma leaps higher as Clinigen mulls possible cash-and-shares offer Wed, 16 Aug 2017 12:58:00 +0100 Midatech’s liver cancer candidate edges closer to human trials as it completes pre-clinical programme Wed, 26 Jul 2017 08:16:00 +0100 Amryt Pharma says long-term study confirms the efficacy of cholesterol drug Tue, 25 Jul 2017 07:30:00 +0100 Midatech Pharma says revenue rose 37% in first half Tue, 18 Jul 2017 08:38:00 +0100 Midatech to investigate brain cancer compound after inking licence deal with Novartis Wed, 07 Jun 2017 15:20:00 +0100 Full steam ahead at Midatech as cancer treatments edge closer to the clinic Wed, 07 Jun 2017 10:45:00 +0100 Amryt Pharma rises as Phase 3 trial of lead candidate enrols first patient Thu, 25 May 2017 09:37:00 +0100 Midatech Pharma selects compound for brain cancer therapy programme Mon, 22 May 2017 08:16:00 +0100 Amryt Pharma hails real world study of cholesterol drug Thu, 27 Apr 2017 13:18:00 +0100 Amryt Pharma phase III study of skin treatment recruits first patient Mon, 24 Apr 2017 07:38:00 +0100 Amryt Pharma achieves impressive first year as publicly traded company, says analyst Thu, 06 Apr 2017 15:38:00 +0100 Drug firm Midatech Pharma prelims chart a year of significant progress Tue, 04 Apr 2017 08:35:00 +0100 Amryt Pharma shares soar as phase III trial for EB gets underway Tue, 28 Mar 2017 09:11:00 +0100 Orphan drug specialist Amryt Pharmaceuticals appoints chief commercial officer Mon, 27 Mar 2017 07:56:00 +0100 New loan for Midatech promises greater profitability Midatech Pharma Plc (LON:MTPH, NASDAQMTP) boss tells us how the company has secured a US$15mln, four-year senior loan facility that will be used to bankroll the clinical development of two promising cancer drug candidates. The funding has come via MidCap Financial, a middle market finance house, and Midtech has drawn down an initial US$7mln of the facility. CEO Jim Phillips tells Proactive what this will mean for Midatech during 2018 while giving us detail on new clinical trials on three different products.

Tue, 02 Jan 2018 14:48:00 +0000
Amryt appoints new Vice President CEO of Amryt Pharmaceutical  (LON:AMYT) Rory Nealon tells Proactive about the latest addition to the senior management team, their new Vice President, Patrick Jordan who will oversee their Lojuxta  business. Jordan is an 18-year veteran of the healthcare industry and has held senior roles at Pfizer and MSD (Merck & Co).
The company is a commercial-stage pharmaceutical company focussed on developing and producing treatments for rare and orphan diseases.
Its lead product, Lojuxta, treats a life-threatening condition called Homozygous Familial Hypercholesterolemia, which causes abnormally high levels of bad cholesterol.

Thu, 21 Dec 2017 09:26:00 +0000
Amryt Pharma signs exclusive Saudi Arabian distribution agreement Dave Allmond, chief commercial officer at  Amryt Pharma PLC (LON:AMYT), discusses with Proactive the exclusive distribution agreement they've signed with Saudi Arabian firm Faisal Musaed El Seif Saudi Pharmaceutical Company.

The deal gives El Seif the right to distribute Amryt’s Lojuxta and AP101 drugs in the kingdom.

Tue, 14 Nov 2017 14:41:00 +0000
Amryt Pharma to raise €15mln for drug to treat rare skin condition Rory Nealon, chief financial officer at Amryt Pharma PLC (LON:AMYT), tells Proactive they're raising €15mln in an oversubscribed share placing – partly to fund the pre-launch costs of a drug for a rare skin condition.

Together with existing cash, the proceeds will be used to bankroll the ongoing phase III trial of  AP101, a potential treatment for Epidermolysis Bullosa.

Thu, 21 Sep 2017 15:24:00 +0100
Lojuxta 'exceeding expectations' - Amryt Pharma's Joe Wiley Joe Wiley, chief executive of Amryt Pharma PLC (LON:AMYT) tells Proactive a product that it licensed the rights to is performing better than expected.

Lojuxta treats a rare and life-threatening condition called Homozygous Familial Hypercholesterolemia, which causes abnormally high levels of bad cholesterol.

Revenues from the treatment were €5.75mln for the six months ended June; the company’s total sales for the period were €6.18mln.

Mon, 04 Sep 2017 10:57:00 +0100
Amryt Pharma making major advances after successful Lojuxta trial Dr Helen Phillips, head of medical affairs at Amryt Pharma PLC (LON:AMYT) discusses with Proactive a recently published long-term study of the drug Lojuxta which further confirmed its efficacy in lowering high cholesterol levels resulting from a rare genetic disorder.

The assessment of Lojuxta, also known as lomitapide, followed the progress of patients with Homozygous Familial Hypercholesterolaemia (HoFH).

Wed, 09 Aug 2017 08:36:00 +0100
Zak Mir: Midatech Pharma looking upwards if it breaks 50-day trend Midatech Pharma Inc (LON:MTPH) can look towards 118p if it can break through the 50-day moving average suggests technical analyst Zak Mir.

Tue, 18 Jul 2017 11:10:00 +0100
Compound selection for brain cancer therapy 'a significant milestone' for Midatech Jim Phillips, chief executive of Midatech Pharma Plc (LON:MTPH NASDAQ:MTP) tells Proactive they've selected their preferred compound candidate for testing as a potential therapy for glioblastoma (GBM), a rare form of brain cancer.

Mon, 22 May 2017 15:01:00 +0100
Amryt Pharma's Dr Helen Phillips on 'remarkable' real-world Lojuxta study Amryt Pharma PLC (LON:AMYT) currently has an exclusive licence to sell Lojuxta to adults in the EU and other territories including the Middle East, North Africa, Turkey and Israel.

Dr Helen Phillips, their head of medical affairs, talks through with Proactive's Andrew Scott their 'unexpected and exciting' findings from a real world study that's been done on the cholesterol-lowering drug.

Fri, 28 Apr 2017 15:58:00 +0100
Amryt Pharma 'delighted' to kick off Episalvan trial Mark Sumeray, chief medical officer for Amryt Pharma PLC (LON:AMYT) tells Proactive's Andrew Scott they're delighted to have enrolled their first patient to the EASE phase III clinical trial of AP101 (Episalvan)

''There's a lot of activity, a lot of time spent in the preparation phase for a big international trial like this, so it's always very exciting to get the first patient entered into the study''.

The EASE study will assess the progress of 164 patients across 30 sites in 15 countries with Sydney, Australia, the first to begin work.

Efficacy will be evaluated by looking at the proportion of wounds completely healed within 45 days.

Tue, 25 Apr 2017 13:51:00 +0100
Midatech Pharma 'consistently delivering on sales growth', says CEO Jim Phillips Jim Phillips, chief executive of Midatech Pharma Plc (LON:MTPH; NASDAQ: MTP) talks Proactive through the firms full year results which chart a year of both operational and financial progress.

The transformation of the business was reflected by top line growth of 510%, with gross revenues coming in at £9.21mln for the 12 months to December 31.

Tue, 04 Apr 2017 11:16:00 +0100
Start of Phase III Episalvan trial 'a momentous time in the history of Amryt' says CFO Rory Nealon Rory Nealon, chief financial officer of Amryt Pharma PLC (LON:AMYT) speaks to Proactive about the start of the company's phase III trial for Episalvan - its treatment for rare skin condition Epidermolysis Bullosa (EB).

Nealon also ran through their full year results to the end of December 2016 as well as discussing the appointment of David Allmond as chief commercial officer.

Thu, 30 Mar 2017 13:28:00 +0100
Amryt Pharma can go as high as 30p, says Zak Mir Leading technical analyst Zak Mir tells the Proactive Investors Bulletin Board he is looking for the Amryt Pharmaceuticals PLC (LON:AMYT) share price to hit 30p in the coming months.

“There’s been a rising trend channel from early summer last year. The floor of the channel is towards the 200-day moving average at 17p,” explains Mir.

“Really while we’re above that notional double support the big target here is as high as 30p at the top of the channel. If you’re cautious on the shares you’d wait for a weekly close above 20p.”

Tue, 28 Mar 2017 09:15:00 +0100
Amryt Pharma's Joe Wiley 'delighted' to soon begin Phase III EB Study Amryt Pharma PLC (LON:AMYT) chief executive Joe Wiley tells Proactive they'll soon begin a phase III clinical trial on a drug for people with a rare skin disorder following the completion of discussions with the US Food & Drug Administration and European Medicines Agency over the design of the study.

Mon, 06 Mar 2017 10:24:00 +0000
£6mln loan facility to help Midatech 'expand and accelerate' growth Midatech Pharma Plc (LON:MTPH, NASDAQ:MTP) chief executive Jim Phillips talks to Proactive about the company's new £6mln loan facility with Silicon Valley Bank to accelerate its cancer-focused product  pipeline.

Mon, 27 Feb 2017 13:46:00 +0000
Can Amryt Pharma add 75% to its share price? Shares in Amryt Pharmaceuticals PLC (LON:AMYT) could gain the best part of 75% over the next few months to hit 28p, according to technical analyst Zak Mir.

“On the technical front, it looks like there’s a broadening triangle after the gap higher at the beginning of December,” Mir explains in the latest Proactive Investors Bulletin Board.

“Support has come in around the 16p area and while we hold that, the top of the triangle at 28p could be the target over the next two to three months.”

Wed, 22 Feb 2017 10:30:00 +0000
Amryt Pharma's COO says Japan patent further boosts potential of lead candidate Rory Nealon, chief operating officer at drug developer Amryt Pharmaceuticals, tells Proactive that receiving a patent grant in Japan extends the group's patent portfolio for lead drug candidate Episalvan (AP101)
Episalvan offers a potential breakthrough for sufferers of Epidermolysis Bullosa (EB), a rare genetic disorder that causes exceptionally fragile skin.
As well as running through the  rest of the AIM firm's pipeline, Nealon explains the product already has coverage up to 2030 in the key US and European markets.

Tue, 07 Feb 2017 14:08:00 +0000
Amryt Pharma makes overnight transformation It’s another day, and another big announcement from Amryt Pharmaceuticals PLC (LON:AMYT), which has unveiled its second major deal in three days.

On Friday, the company’s chief executive, Joe Wiley, popped into the Proactive Investors to speak about a €20mln European Investment Bank loan facility it had signed to fund the late stage development of its lead drug.

He was back again on Monday to talk about an agreement with NASDAQ-listed Aegerion Pharmaceuticals, which brings into the Amryt portfolio the product LOJUXTA, known generically as lomitapide.

A lot of the companies bandy the “transformational” adjective about, but Wiley says it is exactly the right word for the latest deal.

“We have turned overnight from being a clinical development company, with some exciting products in clinical development, to being a fully-fledged commercial pharmaceutical company,” Wiley told Proactive Investors.

The LOJUXTA will be “cash generative from the get-go”, Wiley said.

It’s an impressive achievement for a company that has been in existence just 18 months and which only listed on Aim eight months ago.

“LOJUXTA is a treatment for HoFH, or Homozygous Familial Hypercholesterolemia,” Wiley explained. It is a condition that can even affect babies in the womb.

“What that means is, these are young children that are born with a genetic defect that affects their ability to manage their cholesterol,” Wiley said.

It is the so-called ‘bad cholesterol’ that LOJUXTA will treat, thus reducing the risk of a cardiovascular event, such as a heart attack or stroke.

Distressingly, these children, if untreated, have an average life expectancy of about 18 years.

Amryt will be taking over the marketing of LOJUXTA across the European Economic Area, Middle East and North Africa, Turkey and Israel.

“The product was launched in 2013, it is on a good growth trajectory, and we see significant growth potential for this product in the months and years ahead,” Wiley said.

Mon, 05 Dec 2016 14:50:00 +0000
Amryt boss 'really excited' to have signed milestone funding deal Amryt Pharma plc (LON:AMYT) has secured a €20mln European Investment Bank facility that will help fund a late stage clinical study of a potentially breakthrough treatment for a rare skin disease.

Chief executive Joe Wiley tells Proactive: ''We're really excited to have announced this deal today . A milestone ... it allows us to fund our lead program Episalvan through its pivotal study which is planned for Q1 next year. It also allows us to fund our second product AP 102 into the clinic - so it secures not only our near term but also our midterm funding requirements.''

''We had the opportunity to do an equity raise but we believed that relative to the opportunity that Amryt represents, that our share price is materially undervalued right now, we felt therefore that doing an equity raise, which would be dilutive to shareholders, would be the wrong strategy.''

Early data from patients with Epidermolysis Bullosa (EB) will be available by mid-2018.

EB is an inherited disorder where the skin becomes very fragile. The market for the new treatment is thought to be worth US$1.5bn a year.

Fri, 02 Dec 2016 15:34:00 +0000
Midatech Pharma Plc 'very excited' to take GNP technology into trials Midatech Pharma (LON:MTPH Nasdaq:MTP) is to take its gold-plated nanoparticle technology forward into trials as a treatment for advanced liver cancer.

Chief executive Jim Phillips tells Proactive: ''This is the first time that we've been able to advance a targeted chemotherapy in a way that's not been possible until now, so it's very exciting for us.''

''It's the first targeted chemotherapy that we have developed completely in-house and will be our first one, we hope into patients'', Phillips added.

Compound MTR104 has been selected to start a formal new drug-enabling programme during 2017, with human studies scheduled for 2018.

Tue, 15 Nov 2016 11:36:00 +0000
Orphan drug status for new compound 'great news' says Amryt Pharma PLC's COO Amryt Pharma PLC (LON:AMYT) has been granted orphan drug status in the US for  a compound called AP102 to treat patients with the excess growth condition acromegaly. Chief operating officer Rory Nealon tells Proactive: ''Our focus is to acquire, develop and commercialise products in the orphan drug space ... acromegaly is exactly that, it is classified as an orphan condition with an estimated prevalence of 60 patients per million of population''.
''Orphan status is the same in Europe and the USA - it's designed to encourage companies like ourselves to develop treatments for rare conditions. We get marketing exclusivity and also don't require the same number of patients for clinical trials'', Nealon added. Amryt has already been awarded orphan drug status for its lead drug EpiSalven, to treat the skin disorder Epidermolysis Bullosa, which is being prepared for a phase III trial early next year.

Mon, 07 Nov 2016 14:10:00 +0000
Faron Pharmaceuticals Oy’s options widen after fund-raising Demand for shares in Faron Pharmaceuticals Oy’s (LON:FARN) was strong when the company tapped the City last week for £8mln to fund the development of its two lead drugs.
Faron’s chief executive (CEO), Dr Markku Jalkanen, tells Proactive Investors the fund-raising has brought “quite a number of UK institutional investors” on to the shareholder register.
Some of the new funding will pay for a phase I/II trial in the US of Traumakine, its lead product, in patients with a heart condition called rupture of abdominal aorta aneurysm.
“It’s really important for us to get activities on the US side, specifically for our lead product. We want to conduct a safety trial there, which was the advice given by the [US] Food and Drug Administration, and this will take up maybe half of the proceeds raised at this time,” Dr Jalkanen said.
Some has been kept aside for the pre-clinical and early clinical development of Clevegen, an antibody that could help the body’s own immune system tackle cancer.
“Clevegen is becoming more and more interesting,” the CEO said.
Early stage biotechs are no strangers to fund-raising and there may be another share issue in the offing next year but it is not the only option on the table, Dr Jalkanen said, opening up the possibility of partnership or licensing activities.

Wed, 28 Sep 2016 11:01:00 +0100
Amryt Pharmaceuticals’ Joe Wiley on a busy half year in which it acquired EB drug Episalvan Amryt Pharma chief executive Joe Wiley speaks to Proactive Investors Stocktube about the drug discovery group’s busy half year, which saw two key acquisitions.
“We got a huge amount achieved in a relatively short period of time,”
He added: “We set up Amryt Pharma to be a company focussed on developing and commercialising products in the rare disease or orphan disease space.”
The Amryt boss talks in detail about the group’s newly acquire lead product, Episalvan, to treat a skin disorder called Epidermolysis Bullosa or EB, as well as the company’s portfolio of other treatments.

Tue, 13 Sep 2016 11:37:00 +0100
Faron Pharmaceuticals Oy boss pleased with healthier than expected cash balance Faron Pharmaceuticals Oy (LON:FARN) ended the first half of 2016 with more cash than it had anticipated.

Research & development (R&D) expenses more than doubled, but the combination of higher than anticipated income, in the form of both revenue and grant income, and lower operating costs meant the company experienced only a modest cash outflow over the reporting period.

Chief executive Dr Markku Jalkanen told Proactive revenue comprised mostly of a €750,000 signing fee from Pharmbio and a €356,500 pre-payment relating to IFB-beta production.

The group also received €968,000 from the European Union from its FP7 Traumakine grant.

The company had a cash balance of €8.9mln at the end of June, it revealed in its results for the first half of the year.

Tue, 06 Sep 2016 15:25:00 +0100
Strong sales ''a good validation'' for Midatech Pharma Plc's entry into the US Midatech Pharma Plc (LON:MTPH, NASDAQ:MTP) reported a tenfold year-on-year increase in revenue in the first half of 2016.

Much of the increase was down to the group's acquisition of  cancer supportive care business, DARA Biosciences Inc, which was later renamed Midatech Pharma US Inc (MTPUS).

Chief executive Dr Jim Phillips tells Proactive the results are very much in line with the high-end market expectations they revised them to at the beginning of the year.

A big focus for the business in the first half was on the anti-nausea product Zuplenz, which has been ''a very strong performer and that's really been the driver of growth year-on-year for the commercial side of the business,'' says Philips.

Fri, 02 Sep 2016 13:55:00 +0100
Hybridan’s Pearson cautions biotech investors against knee-jerk reactions to drug trial blips Hybridan’s Niall Pearson tells biotech investors that drug trial failure is ‘the nature of the beast’ and speaking with Proactive Investors he highlighted examples where selling has gone too far.

“When companies have them [trial failures] there’s a big hooha and everyone forgets what they are actually investing in,” Pearson said.

The broker notes Circassia - which recently plummeted more than 60% as a cat allergy treatment trial disappointed - as an example where the market showed a knee-jerk reaction.

Pearson also talked about the ‘long game’ of regaining trust, the importance of diversification, and the opportunities for investing in companies developing drugs for rare diseases and conditions where there are unmet medical needs.

One such example identified by Pearson is Amryt Pharma Plc (LONLAMYT) - a recent addition to the market that will certainly be familiar to avid followers of Proactive Investors.

Thu, 28 Jul 2016 08:13:00 +0100
Amryt Pharma chief looking to “unlock a large market opportunity” Joe Wiley, chief executive of Amryt Pharma PLC (LON:AMYT) says the company is gearing up for a Phase III study for its lead product, Episalvan, for the treatment of epidermolysis bullosa (EB).

The company, which listed on Aim through a reverse takeover of Fastnet Equity, ended May with €12.6mln in cash.

The company is now focused on building a pipeline of drug candidates targeted at treating so-called orphan diseases – serious diseases that affect less than 200,000 people globally.

Wiley says that Episalvan could “unlock a large market opportunity” but also would create a treatment “for a disease for which there’s no other approved therapy right now”.

Amryt aslso has a portfolio of Imlan products, skincare treatments that are 100% natural, and Wile adds that the company is in “active discussions” with a “number of partners” over these products.

Mon, 13 Jun 2016 08:41:00 +0100
Midatech says carcinoid tumour treatment is "very exciting" after good pre-clinical data Jim Phillips, chief executive at Midatech Pharma (LON:MTPH) tells Proactive Investors about the good results from a pre-clinical study of Q-Octreotide, its treatment for the side effects of carcinoid tumours.

The company has "a really exciting product that is the next generation of that type of therapy," says Phillips.

The company is investing to scale up production at its Bilbao site in Spain so it can start to commercially produce the treatment. It is also preparing for the clinical trial that will start at the end of the year/beginning of next year.

Tue, 26 Apr 2016 14:09:00 +0100
Midatech chief confident OpsiSporin will reach market Midatech Pharma PLC (LON:MTPH, NASDAQ:MTP) said a study it is conducting on a treatment for an inflammatory eye disorder delivered some encouraging results.

Its preclinical work was designed to assess the efficacy of drug candidate OpsiSporin in treating uveitis.

Jim Phillips, chief executive, tells Proactive Investors the treatment could be “one of the first really localised effective treatments for this condition”.

He says that the product will take two to three years of clinical studies with the product likely to be marketed by 2020-2021 adding that “because it is using an active ingredient that we know works and that the data we’ve now produced is good, it makes us increasingly confident that it will reach market”.

Fri, 22 Apr 2016 11:16:00 +0100
Faron Pharma chief hopes for global patent protection for Clevegen Markku Jalkanen, chief executive of Faron Pharmaceuticals Ltd (LON:FARN), says he expects Clevegen, a drug that uses the body’s own immune system to kill cancer, to be granted patent protection globally as it is a unique treatment able to “destroy both the antibody and the receptor”.

Faron has filed two patents to protect the drug, which, put simply, converts the environment around a tumour from being suppressive to immune stimulating.

Jalkanen adds that the company believes there are other diseases where “similar immune-suppressive activities [could be] involved”, including tuberculosis, and the patent application opens up new opportunities for these further applications.

Tue, 19 Apr 2016 11:03:00 +0100